Oliver Feeney, Julian Cockbain, Michael Morrison, Lisa Diependaele, Kristof Van Assche & Sigrid Sterckx
American Journal of Bioethics 18 (12):36-48 (2018)
AbstractIn 2012, a new and promising gene manipulation technique, CRISPR-Cas9, was announced that seems likely to be a foundational technique in health care and agriculture. However, patents have been granted. As with other technological developments, there are concerns of social justice regarding inequalities in access. Given the technologies’ “foundational” nature and societal impact, it is vital for such concerns to be translated into workable recommendations for policymakers and legislators. Colin Farrelly has proposed a moral justification for the use of patents to speed up the arrival of technology by encouraging innovation and investment. While sympathetic to his argument, this article highlights a number of problems. By examining the role of patents in CRISPR and in two previous foundational technologies, we make some recommendations for realistic and workable guidelines for patenting and licensing.
Similar books and articles
CRISPR as a Driving Force: The Model T of Biotechnology.Carlos Mariscal & Angel Petropanagos - 2016 - Monash Bioethics Review 34 (2):1-16.
“Editing”: A Productive Metaphor for Regulating CRISPR.Ben Merriman - 2015 - American Journal of Bioethics 15 (12):62-64.
Similar or the Same? Why Biosimilars Are Not the Solution.Lisa Diependaele, Julian Cockbain & Sigrid Sterckx - 2018 - Journal of Law, Medicine and Ethics 46 (3):776-790.
Everything in Moderation, Even Hype: Learning From Vaccine Controversies to Strike a Balance with CRISPR.Shawna Benston - 2017 - Journal of Medical Ethics 43 (12):819-823.
Review of Becoming Biosubjects: Bodies, Systems, Technologies. [REVIEW]Audrey L'Espérance - 2012 - Studies in Social Justice 6 (1):147-149.
Germline Manipulation and Our Future Worlds.John Harris - 2015 - American Journal of Bioethics 15 (12):30-34.
CRISPR Critters and CRISPR Cracks.R. Alta Charo & Henry T. Greely - 2015 - American Journal of Bioethics 15 (12):11-17.
Brains, Trains and Automobiles: An Editorial.Anthony Mark Cutter & Bert Gordijn - 2008 - Studies in Ethics, Law, and Technology 2 (1).
A Use/Disuse Paradigm for CRISPR-Cas Systems.Sophie Veigl - 2019 - Biology and Philosophy 34 (1):13.
Protecting Humanity Habermas and His Critics on the Ethics of Emerging Biotechnologies.Matti Hayry - 2012 - Cambridge Quarterly of Healthcare Ethics 21 (2):211-222.
Is CRISPR an Ethical Game Changer?Marcus Schultz-Bergin - 2018 - Journal of Agricultural and Environmental Ethics 31 (2):219-238.
Exploiting CRISPR/Cas Systems for Biotechnology.Timothy R. Sampson & David S. Weiss - 2014 - Bioessays 36 (1):34-38.
Environmentally Virtuous Agriculture: How and When External Goods and Humility Ethically Constrain Technology Use.J. Barker Matthew & Lettner Alana Friend - 2017 - Journal of Agricultural and Environmental Ethics 30 (2):287-309.
Potential Expectations of Biotechnologies: A Model for the Analysis of Conflicts About New Technologies.Andreas Kaminski - 2015 - Filozofija I Društvo 26 (3):519-539.
Ethical Issues of Using CRISPR Technologies for Research on Military Enhancement.Marsha Greene & Zubin Master - 2018 - Journal of Bioethical Inquiry 15 (3):327-335.
Added to PP
Historical graph of downloads
Citations of this work
The Human Right to Science and Foundational Technologies.Andrea Boggio & Calvin W. L. Ho - 2018 - American Journal of Bioethics 18 (12):69-71.
The View of CRISPR Patents Through the Lens of Solidarity and the Public Good.Benjamin Capps, John J. Mulvihill, Yann Joly & Tamra Lysaght - 2018 - American Journal of Bioethics 18 (12):54-56.
Gene Patents and the Social Justice Lens.Colin Farrelly - 2018 - American Journal of Bioethics 18 (12):49-51.
Foundational Technologies and Legal Realities.Andreas Kuersten - 2018 - American Journal of Bioethics 18 (12):65-67.
Foundational Technologies and Accountability.Stephen Hilgartner - 2018 - American Journal of Bioethics 18 (12):63-65.
References found in this work
Making Dollars Out of DNA: The First Major Patent in Biotechnology and the Commercialization of Molecular Biology, 1974-1980.Sally Smith Hughes - 2001 - Isis 92 (3):541-575.